Table 1.
Patient characteristics
| Cotreatment | Cyclosporine | Tacrolimus |
|---|---|---|
| Gender (men/women) | 88/52 | 73/28 |
| Age (years) | 50 (19 to 70) | 53 (19 to 76) |
| Length (cm) | 170 (150 to 190) | 175 (150 to 195) |
| Body weight (kg) | 69 (37 to 104) | 80 (44 to 145) |
| Time posttransplantation (days) | 26 (1 to 152) | 23 (3 to 168) |
| Creatinine (μmol/L) | 141 (53 to 1238) | 145 (61 to 1190) |
| Albumin (g/L) | 36 (20 to 53) | 39 (10 to 50) |
| ASAT (U/L) | 14 (2 to 289) | 21 (8 to 236) |
| ALAT (U/L) | 14 (1 to 653) | 24 (1 to 534) |
| PK-day | 26 (4 to 152) | 23 (3 to 168) |
| MMF dose two times daily (mg) | 1150 (250 to 2200) | 750 (250 to 1500) |
| CNI daily dose (mg) | 450 (125 to 2100) | 8 (1 to 20) |
Parameters are presented as median (range), separated for the cotreatment of the calcineurin inhibitors, cyclosporine, and tacrolimus. ASAT, aspartate aminotransferase; ALAT, alanine transaminase; CNI, calcineurin inhibitors; PK-day, number of days between the transplantation and the pharmacokinetic assessment.